Compounds > naproxen
Page last updated: 2024-09-04

naproxen and tetracycline

naproxen has been researched along with tetracycline in 24 studies

Compound Research Comparison

Studies
(naproxen)		Trials
(naproxen)		Recent Studies (post-2010)
(naproxen)		Studies
(tetracycline)		Trials
(tetracycline)		Recent Studies (post-2010) (tetracycline)
4,5511,0571,42921,5249773,656

Protein Interaction Comparison

ProteinTaxonomynaproxen (IC50)tetracycline (IC50)
90-kda heat shock protein beta HSP90 beta, partialHomo sapiens (human)22.4474
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)22.4474
tyrosine-protein phosphatase non-receptor type 7 isoform 2Homo sapiens (human)8.33
30S ribosomal protein S6Escherichia coli K-124.58
30S ribosomal protein S7Escherichia coli K-124.58
50S ribosomal protein L15Escherichia coli K-124.58
50S ribosomal protein L10Escherichia coli K-124.58
50S ribosomal protein L11Escherichia coli K-124.58
50S ribosomal protein L7/L12Escherichia coli K-124.58
50S ribosomal protein L19Escherichia coli K-124.58
50S ribosomal protein L1Escherichia coli K-124.58
50S ribosomal protein L20Escherichia coli K-124.58
50S ribosomal protein L27Escherichia coli K-124.58
50S ribosomal protein L28Escherichia coli K-124.58
50S ribosomal protein L29Escherichia coli K-124.58
50S ribosomal protein L31Escherichia coli K-124.58
50S ribosomal protein L31 type BEscherichia coli K-124.58
50S ribosomal protein L32Escherichia coli K-124.58
50S ribosomal protein L33Escherichia coli K-124.58
50S ribosomal protein L34Escherichia coli K-124.58
50S ribosomal protein L35Escherichia coli K-124.58
50S ribosomal protein L36Escherichia coli K-124.58
30S ribosomal protein S10Escherichia coli K-124.58
30S ribosomal protein S11Escherichia coli K-124.58
30S ribosomal protein S12Escherichia coli K-124.58
30S ribosomal protein S13Escherichia coli K-124.58
30S ribosomal protein S16Escherichia coli K-124.58
30S ribosomal protein S18Escherichia coli K-124.58
30S ribosomal protein S19Escherichia coli K-124.58
30S ribosomal protein S20Escherichia coli K-124.58
30S ribosomal protein S2Escherichia coli K-124.58
30S ribosomal protein S3Escherichia coli K-124.58
30S ribosomal protein S4Escherichia coli K-124.58
30S ribosomal protein S5Escherichia coli K-124.58
30S ribosomal protein S8Escherichia coli K-124.58
30S ribosomal protein S9Escherichia coli K-124.58
50S ribosomal protein L13Escherichia coli K-124.58
50S ribosomal protein L14Escherichia coli K-124.58
50S ribosomal protein L16Escherichia coli K-124.58
50S ribosomal protein L23Escherichia coli K-124.58
30S ribosomal protein S15Escherichia coli K-124.58
50S ribosomal protein L17Escherichia coli K-124.58
50S ribosomal protein L21Escherichia coli K-124.58
50S ribosomal protein L30Escherichia coli K-124.58
50S ribosomal protein L6Escherichia coli K-124.58
30S ribosomal protein S14Escherichia coli K-124.58
30S ribosomal protein S17Escherichia coli K-124.58
30S ribosomal protein S1Escherichia coli K-124.58
50S ribosomal protein L18Escherichia coli K-124.58
Alpha-synucleinHomo sapiens (human)6.06
50S ribosomal protein L2Escherichia coli K-124.58
50S ribosomal protein L3Escherichia coli K-124.58
50S ribosomal protein L24Escherichia coli K-124.58
50S ribosomal protein L4Escherichia coli K-124.58
50S ribosomal protein L22Escherichia coli K-124.58
50S ribosomal protein L5Escherichia coli K-124.58
30S ribosomal protein S21Escherichia coli K-124.58
50S ribosomal protein L25Escherichia coli K-124.58
50S ribosomal protein L36 2Escherichia coli K-124.58

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19902 (8.33)18.7374
1990's4 (16.67)18.2507
2000's7 (29.17)29.6817
2010's11 (45.83)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abelman, MM; Batt, DG; Bostrom, LL; Corbett, RL; Decicco, CP; Di Meo, SV; Freimark, B; Giannaras, JV; Petraitis, JJ; Wright, SW1
Strassburg, CP; Tukey, RH1
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL1
Caron, G; Ermondi, G; Lorenti, M1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Bellman, K; Knegtel, RM; Settimo, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Clark, JS; Jubb, SN; Maloney, PJ; Young, JM1
Ballaron, SJ; De Young, LM; Puhvel, SM; Spires, DA; Young, JM1
Chan, CS; Chan, FK; Chung, SC; Lee, YT; Leung, VK; Li, EK; Sung, JJ; To, KF; Woo, J; Yung, MY1
Metz, DC1
Fendrick, AM; Jeffries, MA; Scheiman, JM1
Chan, FK; Chan, HL; Chung, SC; Hui, Y; Lai, MS; Lau, JY; Lee, YT; Leung, VK; Leung, WK; Suen, BY; Sung, JJ; Wu, JC1
Han, HK; Oh, YH1

Reviews

2 review(s) available for naproxen and tetracycline

ArticleYear
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
    Annual review of pharmacology and toxicology, 2000, Volume: 40

    Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic

2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

4 trial(s) available for naproxen and tetracycline

ArticleYear
Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.
    Lancet (London, England), 1997, Oct-04, Volume: 350, Issue:9083

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Drug Administration Schedule; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Naproxen; Organometallic Compounds; Prospective Studies; Stomach Ulcer; Tetracycline

1997
Eradicate the bug before you start the drug?
    The American journal of gastroenterology, 1998, Volume: 93, Issue:2

    Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Naproxen; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Tetracycline

1998
Helicobacter pylori eradication: kill the bug and save the pill?
    The American journal of gastroenterology, 1998, Volume: 93, Issue:7

    Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Naproxen; Peptic Ulcer; Prospective Studies; Risk Factors; Single-Blind Method; Tetracycline

1998
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.
    The New England journal of medicine, 2001, Mar-29, Volume: 344, Issue:13

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Naproxen; Omeprazole; Organometallic Compounds; Secondary Prevention; Tetracycline

2001

Other Studies

18 other study(ies) available for naproxen and tetracycline

ArticleYear
Heteroaryl-fused 2-phenylisothiazolone inhibitors of cartilage breakdown.
    Journal of medicinal chemistry, 1994, Sep-16, Volume: 37, Issue:19

    Topics: Animals; Cartilage; Cattle; Dose-Response Relationship, Drug; Humans; Interleukin-1; Isomerism; Male; Metalloendopeptidases; Models, Biological; Proteoglycans; Pyridines; Pyrimidines; Rats; Structure-Activity Relationship; Thiazoles

1994
Cheminformatic models to predict binding affinities to human serum albumin.
    Journal of medicinal chemistry, 2001, Dec-06, Volume: 44, Issue:25

    Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids

2001
Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction.
    Journal of medicinal chemistry, 2004, Jul-29, Volume: 47, Issue:16

    Topics: Chromatography, Affinity; Hydrogen-Ion Concentration; Ions; Models, Molecular; Molecular Conformation; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Serum Albumin, Bovine; Ultracentrifugation

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
    Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
Pharmacological investigation of the mechanisms of platelet-activating factor induced mortality in the mouse.
    Prostaglandins, 1985, Volume: 30, Issue:4

    Topics: Anaphylaxis; Animals; Chloroquine; Chlortetracycline; Dexamethasone; Dose-Response Relationship, Drug; Female; Indomethacin; Injections, Intravenous; Male; Mice; Mice, Inbred DBA; Naproxen; Nicardipine; Nifedipine; Platelet Activating Factor; Pyrazoles; Quinacrine; Tetracycline; Verapamil

1985
Intradermal injection of Propionibacterium acnes: a model of inflammation relevant to acne.
    The Journal of investigative dermatology, 1984, Volume: 83, Issue:5

    Topics: Acne Vulgaris; Animals; Benzoyl Peroxide; Disease Models, Animal; Erythromycin; Female; Fluocinolone Acetonide; Inflammation; Injections, Intradermal; Naproxen; Propionibacterium acnes; Pyrazoles; Rats; Rats, Inbred Strains; Tetracycline; Tretinoin

1984
Pharmacokinetic interaction of tetracycline with non-steroidal anti-inflammatory drugs via organic anion transporters in rats.
    Pharmacological research, 2006, Volume: 53, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Interactions; Male; Metabolic Clearance Rate; Naproxen; Organic Anion Transporters; Rats; Rats, Sprague-Dawley; Tetracycline

2006